IL2 and graft versus host disease: Furthermore, preclinical trial data suggest that GVHD after allo-HSCT can be controlled in patients with low numbers of Tregs stimulated by TL1A-Ig combined with IL-2, as this method of amplification can enhance Tregs’ suppressive activity (16).